Millennium Management Llc Rotates From AI Winners Into Banks And Broad Beta

The biggest adds by dollars show Millennium leaning into financial plumbing and low-cost beta, not chasing another leg up in the same AI leaders. They are effectively upgrading their how they own the market, while expressing strong views on which balance sheets and business models benefit from the current macro regime.

On the ETF side, the reshuffle is stark:

• SPYM is a new $1.65B position at 1.23% of the book, an immediate-scale bet on a factor-tilted S&P variant rather than generic SPY.
• VOO is ramped to $607.6M (0.45%) from a rounding error, a clean, low-cost S&P core.

Financials are the clearest single-theme add:

• Bank of America rockets higher, with shares up +486.5% and about $577.0M of incremental capital despite the position sitting slightly below average cost.
• CBRE’s stake jumps +355.0% with roughly $453.9M added even though the fund is currently down vs. its average buy price, signaling a willingness to average into a disliked real estate cyclically exposed name.
• Huntington Bancshares explodes +986.6% in shares, and Citigroup is boosted +37.4%, rounding out a coordinated push into money-center and regional banks.

They are simultaneously pressing high-beta or bruised single-name equity stories:

• Meta and Microsoft both see sizable increases, with around $512.3M and $187.7M added respectively — but these are at only modest gains vs cost, more like fresh-growth capital than late profit-taking.
• Warner Bros Discovery is lifted +71.6% by shares, adding about $503.3M, a bold vote that this heavily scrutinized media balance sheet still has real equity optionality.
• Tesla’s shares are up +341.5%, with roughly $452.2M added, reframing it as a core industrial/auto exposure rather than a marginal trading line.
• Coterra Energy is boosted +542.1% by shares (about $377.7M), and BP is nearly doubled, reflecting a renewed interest in cash-generative energy at non-bubble valuations.
• In healthcare, Bristol-Myers’ stake is multiplied (shares up +780.2%, about $351.9M added), while Hologic and Penumbra are both materially increased, suggesting a rotation into underloved medtech and big pharma rather than the already-crowded quality-healthcare basket.

Taken together, the buying pattern reads like a barbell: market beta and financial infrastructure on one end, plus a handpicked set of stressed or early-cycle recovery names on the other.

The funding sources are telling: Millennium is not selling risk so much as it is selling winners. The most aggressive cuts come from hyper-liquid, consensus exposures where they are sitting on fat gains.

In ETFs, they dramatically reshape the S&P toolkit:

• SPY is slashed by -82.9% of shares, freeing roughly $2.0B.
• IVV is trimmed -10.4%, releasing about $985.3M while still a hefty 6.34% position.

In AI and mega-cap tech, they are bluntly taking chips off the table:

• Nvidia is cut -30.5%, unlocking about $810.6M; the position still sits more than 100% above average cost.
• Broadcom is halved (shares -51.6%), freeing about $710.1M after a strong run.
• Both Alphabet share classes are trimmed hard: GOOGL down -38.0% (about $293.6M) and GOOG down -28.8% (about $206.9M), even though both still show triple-digit gains vs cost.

Outside tech, the pattern rhymes: monetize liquidity, not conviction.

• The iShares Bitcoin Trust is reduced -43.8% in shares, crystallizing a loss vs cost but shrinking an inherently volatile sleeve by about $578.1M.
• Freeport-McMoRan, Nvent, and Chevron are all meaningfully cut, collectively freeing hundreds of millions from cyclical materials, industrial components, and integrated oil after strong absolute moves.
• Intuitive Surgical is reduced -38.8% despite being underwater vs average cost, likely a risk-budget call inside healthcare after adding to other, cheaper names.

This is consistent multi-asset pruning: sell the names and vehicles that have become position-size and sentiment outliers, reallocate into areas where valuation and cyclicality offer a better risk-reward over the next leg.

Sector math confirms what the single-name moves already hinted: Millennium is deliberately rotating away from concentrated, idiosyncratic AI risk toward financials, diversified beta, and a broader cyclical mix.

Technology’s weight falls from 28.41% to 24.01%, even as they top up selective semis like Micron and Marvell. The net effect is a tilt away from the most crowded AI beneficiaries (Nvidia, Broadcom, Alphabet) and toward a more balanced set of hardware and platform exposures.

Finance is the standout gainer, jumping from 8.15% to 13.02%. That isn’t an incidental drift — it is a deliberate sector call expressed through money-center banks (Bank of America, Citigroup, JPMorgan trims but still sizable), brokers and asset managers (Morgan Stanley, BlackRock, Invesco, StepStone), and real estate-linked CBRE. This is a bet that higher-for-longer rates and a normalized credit cycle are positives, not systemic risks.

Unclassified holdings — mostly ETFs — shrink from 37.78% to 34.5% even as SPYM and VOO are added, because SPY is gutted. Effectively, they are reshaping their passive core rather than simply de-risking it, tilting towards cheaper and more factor-conscious wrappers.

Below the headline sectors, the book edges more cyclical: Industrials rise from 6.06% to 7.1% with big additions to Tesla, Norfolk Southern, and IDEX, while Real Estate (driven by Mastercard’s classification here and CBRE) climbs from 0.36% to 1.03%. Utilities, Energy, and Health Care all tick up modestly, reflecting broad-based rebalancing rather than a single heroic macro call.

Viewed in aggregate, this quarter’s 13F paints Millennium as a manager preparing for mean reversion in both macro and market leadership, not a continuation of straight-line AI and mega-cap dominance. They are not abandoning tech — far from it — but they are clearly less willing to let a handful of AI winners and a Bitcoin ETF dictate their risk outcome.

The rising Finance weight, paired with larger stakes in money-center and regional banks plus asset managers and CBRE, implies a view that credit losses remain manageable and that capital-markets activity, wealth flows, and rate spreads can support earnings from here. If they were bracing for a hard landing, this is not how they would be positioned.

On the equity factor side, the shift from SPY and a chunk of IVV toward SPYM and VOO suggests a more intentional construction of beta: own the market cheaply, and express style tilts via specific wrappers instead of hoping the cap-weighted S&P keeps being a pure AI-and-Mag7 trade. That gives them cleaner levers to add or subtract risk as leadership broadens or narrows.

Finally, the adds to Warner Bros Discovery, Tesla, Coterra, Bristol-Myers, and select medtech names signal a willingness to own controversy at a price. This is not a defensive de-gross; it is a re-underwriting of where the next two to three years of alpha might come from if dispersion remains high. Expect future quarters to keep rhyming with this one: incremental profit-taking in crowded winners, incremental size in underowned, rate- and cycle-sensitive assets that benefit if the world looks merely “okay” rather than perfect.